Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ALE.C04 |
Synonyms | |
Therapy Description |
ALE.C04 is a monoclonal antibody that targets CLDN1, potentially leading to enhanced T-lymphocyte infiltration and inhibition of tumor growth (Cancer Res (2023) 83 (8_Supplement): LB284). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ALE.C04 | ALE C04|ALE-C04|ALEC04 | ALE.C04 is a monoclonal antibody that targets CLDN1, potentially leading to enhanced T-lymphocyte infiltration and inhibition of tumor growth (Cancer Res (2023) 83 (8_Supplement): LB284). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06054477 | Phase Ib/II | ALE.C04 + Pembrolizumab ALE.C04 Pembrolizumab | Study of ALE.C04 in Patients With Head and Neck Cancer | Recruiting | USA | ITA | FRA | ESP | CHE | CAN | 2 |